Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation
暂无分享,去创建一个
Martha J. Radford | Brian F. Gage | Michael Boechler | M. Rich | B. Gage | M. Radford | A. Waterman | W. Shannon | M. Boechler | Michael W. Rich | Amy D. Waterman | William D. Shannon
[1] P. Duncan,et al. Inaccuracy of the International Classification of Diseases (ICD-9-CM) in identifying the diagnosis of ischemic cerebrovascular disease , 1997, Neurology.
[2] W. J. Hamilton,et al. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.
[3] P. Allison. Survival analysis using the SAS system : a practical guide , 1995 .
[4] Elisa T. Lee,et al. Statistical Methods for Survival Data Analysis , 1994, IEEE Transactions on Reliability.
[5] R McBride,et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. , 1999, Stroke.
[6] O. Benavente,et al. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.
[7] R. Kronmal,et al. Stroke risk in an elderly population with atrial fibrillation , 1999, Journal of General Internal Medicine.
[8] R B D'Agostino,et al. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. , 1994, Stroke.
[9] D. Einstadter,et al. Atrial fibrillation as a risk factor for stroke: a retrospective cohort study of hospitalized Medicare beneficiaries. , 1998, American journal of public health.
[10] R. Cheung. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. , 1998, JAMA.
[11] D. Singer,et al. Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. , 1991, The American journal of medicine.
[12] Rose Anne Kenny,et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community , 1998, The Lancet.
[13] D. Armstrong,et al. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation , 1999, BMJ.
[14] R. Hart. Warfarin in atrial fibrillation: underused in the elderly, often inappropriately used in the young , 1999, Heart.
[15] E. Ziegel,et al. Bootstrapping: A Nonparametric Approach to Statistical Inference , 1993 .
[16] K. Flegel,et al. Risk factors for stroke and other embolic events in patients with nonrheumatic atrial fibrillation. , 1989, Stroke.
[17] B. Gage,et al. The Effect of Stroke and Stroke Prophylaxis With Aspirin or Warfarin on Quality of Life , 1996 .
[18] S. Jencks,et al. The health care quality improvement initiative. A new approach to quality assurance in Medicare. , 1992, JAMA.
[19] Elisa T. Lee,et al. Statistical Methods for Survival Data Analysis , 1994, IEEE Transactions on Reliability.
[20] A. Algra,et al. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group. , 1995, Stroke.
[21] Frank J. Hildner,et al. ArticlesAntithrombotic Therapy in Atrial Fibrillation , 1989 .
[22] D. Singer,et al. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. , 2000, Circulation.
[23] B. Gersh,et al. Lone atrial fibrillation in elderly persons: a marker for cardiovascular risk. , 1999, Archives of internal medicine.
[24] Daniel B. Mark,et al. TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .
[25] D B Hier,et al. Parametric modeling of stroke recurrence. , 1994, Neuroepidemiology.
[26] Leandro Provinciali,et al. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .
[27] J. Knottnerus,et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin , 1999, BMJ.
[28] J. Halperin,et al. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. , 2000, The American journal of medicine.
[29] A Laupacis,et al. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. , 1999, JAMA.
[30] B. Gage,et al. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. , 1998, Stroke.
[31] D K Owens,et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. , 1995, JAMA.
[32] J. Hirsh,et al. Management of anticoagulation before and after elective surgery. , 1997, The New England journal of medicine.